Sarepta Therapeutics: Not So Fast
May 25, 2016 at 12:10 PM EDT
Leerink's Joseph Schwartz and Dae Gon Ha aren't buying the bullish argument that a delayed FDA decision on Sarepta Therapeutics' ( SRPT ) Duchenne muscular dystrophy drug is good news. They explain why:
